Medical treatment of prolactinomas

Endocrinology and Metabolism Clinics of North America

Volumn 28, Issue 1, 1999, Pages 143-169

  Molitch, M E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE MESILATE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE MESILATE; QUINAGOLIDE;

COMPUTER ASSISTED TOMOGRAPHY; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; INFERTILITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REVIEW; SEXUAL DYSFUNCTION; TREATMENT INDICATION; TUMOR VOLUME;

EID: 0032964305     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70061-X     Document Type: Article

References (169)

1. S.R. Ahmed S.M. Shalet Discordant responses of prolactinoma to two different dopamine agonists Clin Endocrinol 24 1986 421 426
2. A.C. Andreotti E. Pianezzola S. Persiani Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers J Clin Endocrinol Metab 80 1995 841
3. M. Anniko J. Wersäll Clinical and morphological findings in two cases of bromocriptine-treated prolactinomas Acta Pathol Microbiol Scand 89 1981 41 47
4. M.B. Arafah K.E. Neki R.S. Gold Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas J Clin Endocrinol Metab 80 1995 3507 3512
5. M.A. Arnaout T.L. Garthwaite D.R. Martinson Vasoactive intestinal polypeptide is synthesized in anterior pituitary tissue Endocrinology 119 1988 2052 2057
6. A. Barlier I. Pellegrini-Bouiller I. Caccavelli Abnormal transduction mechanisms in pituitary adenomas Horm Res 47 1997 227 234
7. D.L. Barrow G.T. Tindall K. Kovacs Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumors J Neurosurg 60 1984 1 7
8. M. Berezin D. Avidan E. Baron Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dopaminergic drugs Isr J Med Sci 27 1991 375 379
9. J.S. Bevan C.B.T. Adams C.W. Burke Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including preoperative bromocriptine therapy Clin Endocrinol 26 1987 541 556
10. J.S. Bevan C.W. Burke M.M. Esiri Misinterpretation of prolactin levels leading to management errors in patients with sellar enlargement Am J Med 82 1987 29 32
11. J.S. Bevan J. Webster C.W. Burke Dopamine agonist and pituitary tumor shrinkage Endocr Rev 13 1992 220 240
12. B.M.K. Biller M.E. Molitch M.L. Vance Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline J Clin Endocrinol Metab 81 1996 2338 2343
13. R.E. Blackwell E.L. Bradley L.B. Kline Comparison of dopamine agonists in the treatment of hyperprolactinemic syndromes: A multicenter study Fertil Steril 39 1983 744 748
14. J.F. Bonneville D. Poulignot F. Cattin Computed tomographic demonstration of the effects of bromocriptine on pituitary microadenoma size Radiology 143 1982 451 455
15. J.V. Bowler I.E. Ormerod N.J. Legg Retroperitoneal fibrosis and bromocriptine Lancet 2 1986 466
16. Boyd A.E. III S. Spare B. Bower Neurogenic galactorrhea-amenorrhea J Clin Endocrinol Metab 47 1978 1374 1377
17. J.B. Brodsky E.N. Cohen Brown B.W. Jr Surgery during pregnancy and fetal outcome Am J Obstet Gynecol 138 1980 1165 1167
18. T. Brue I. Pellegrini A. Priou Prolactinomas and resistance to dopamine agonist Horm Res 38 1992 84 89
19. J.R. Burgess J.J. Shepherd V. Parameswaran Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: Clinical features and inheritance pattern J Clin Endocrinol Metab 81 1996 1841 1845
20. J.R. Burgess J.J. Shepherd V. Parameswaran Spectrum of pituitary disease in multiple endocrine neoplasia type 1 (MEN 1): Clinical, biochemical, and radiological features of pituitary disease in a large MEN 1 kindred J Clin Endocrinol Metab 81 1996 2642 2646
21. 2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas Neuroendocrinology 60 1994 314 322
22. E.S. Canales I.C. Garcia J.E. Ruíz Bromocriptine as prophylactic therapy in prolactinoma during pregnancy Fertil Steril 36 1981 524 526
23. E. Ciccarelli M. Giusti C. Miola Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients J Clin Endocrinol Metab 69 1989 725 728
24. R.N. Clayton M. Boggild A.S. Bates Tumour suppressor genes in the pathogenesis of human pituitary tumours Horm Res 47 1997 185 193
25. A. Colao A. DeSarno M.L. Landi Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage J Clin Endocrinol Metab 82 1997 3574 3579
26. A. Colao A. DiSarno S. Sarnacchiaro Prolactinomas resistant to standard dopamine-agonists respond to chronic cabergoline treatment J Clin Endocrinol Metab 82 1997 876 883
27. B. Corenblum P.J. Taylor Long-term follow-up of hyperprolactinemic women treated with bromocriptine Fertil Steril 40 1983 596 599
28. B. Corenblum B.R. Webster C.B. Mortimer Possible anti-tumour effect of 2 patients with large prolactin-secreting pituitary adenomas Clin Res 23 1975 614A
29. P.G. Crosignani A. Mattei C. Ferrari Enlargement of a prolactin-secreting pituitary microadenoma during bromocriptine treatment Br J Obstet Gynecol 89 1982 169 170
30. D. Dallabonzana B. Spelta G. Oppizzi Reenlargement of macroprolactinomas during bromocriptine treatment: Report of two cases J Endocrinol Invest 6 1983 47 50
31. G.W. Dalzell A.B. Atkinson D.J. Carson Normal growth and pubertal development during bromocriptine treatment for a prolactin-secreting pituitary macroadenoma Clin Endocrinol 26 1987 169 172
32. E. Delgrange D. Maiter J. Donckier Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine Eur J Endocrinol 134 1996 454 456
33. J.F. Demonet M. Rostin J.M. Dueymes Retroperitoneal fibrosis and treatment of Parkinson's disease with high doses of bromocriptine Clin Neuropharmacol 9 1986 200 201
34. R. Demura O. Kubo H. Demura Changes in computed tomographic findings in microprolactinomas before and after bromocriptine Acta Endocrinol 110 1985 308 312
35. E. DiSalle G. Ornati D. Giudici A comparison of the in vivo and in vitro duration of prolactin lowering effect in rats of FCE 21336, pergolide and bromocriptine J Endocrinol Invest 7 suppl 1 1984 32
36. Divers W.A. Jr S.S.C. Yen Prolactin-producing microadenomas in pregnancy Obstet Gynecol 61 1983 425 429
37. L. Duranteau P. Chanson A. Lavoinne Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas Clin Endocrinol 34 1991 25 29
38. A.D. Elster Modern imaging of the pituitary Radiology 187 1993 1 14
39. M.M. Esiri J.S. Bevan C.W. Burke Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland J Clin Endocrinol Metab 63 1986 383 388
40. G. Faglia P. Moriondo P. Travaglini Influence of previous bromocriptine therapy on surgery for microprolactinoma Lancet 1 1983 133 134
41. R. Fahlbusch M. Buchfelder Influence of preoperative bromocriptine therapy on success of surgery for microprolactinoma Lancet 2 1984 519 520
42. R. Fahlbusch M. Buchfelder U. Schrell Short-term preoperative treatment of macroprolactinomas by dopamine agonist J Neurosurg 67 1987 807 815
43. S.L. Feigenbaum D.E. Downey C.B. Wilson Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: Long term follow-up J Clin Endocrinol Metab 81 1996 1711 1719
44. C.I. Ferrari R. Abs J.S. Bevan Treatment of macroprolactinoma with cabergoline: A study of 85 patients Clin Endocrinol 46 1997 409 413
45. C. Ferrari C. Barbieri R. Caldara Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients J Clin Endocrinol Metab 63 1986 941 945
46. C. Ferrari A. Mattei G.B. Melis Cabergoline: Long-acting oral treatment of hyperprolactinemic disorders J Clin Endocrinol Metab 68 1989 1201 1206
47. C. Ferrari A. Paracchi A.M. Mattei Cabergoline in the long-term therapy of hyperprolactinemic disorders Acta Endocrinol 126 1992 489 494
48. S.A. Fine L.A. Frohman Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors J Clin Invest 61 1978 973 980
49. S.M. Foord J.R. Peters C. Dieguez Dopamine receptors on intact anterior pituitary cells in culture: Functional association with the inhibition of prolactin and thyrotropin Endocrinology 112 1983 1567 1577
50. S. Franks S.S. Lynch P.M. Horrocks Treatment of hyperprolactinaemia with pergolide mesylate: Acute effects and preliminary evaluation of long-term treatment Lancet 2 1981 659 661
51. C. Gemzell C.F. Wang Outcome of pregnancy in women with pituitary adenoma Fertil Steril 31 1979 363 372
52. L.E. Gluskin B. Strasberg J.H. Shah Verapamil-induced hyperprolactinemia and galactorrhea Ann Intern Med 95 1981 66 67
53. R. Gonsky V. Herman S. Melmed Transforming DNA sequences present in human prolactin-secreting pituitary tumors Mol Endocrinol 5 1991 1687 1695
54. A. Grossman R. Ross J.A.H. Wass Depot-bromocriptine treatment for prolactinomas and acromegaly Clin Endocrinol 24 1986 231 238
55. T.C. Hagen M.A. Arnaout W.J. Scherzer Antisera to vasoactive intestinal polypeptide inhibit basal prolactin release from dispersed anterior pituitary cells Neuroendocrinology 43 1986 641 645
56. V. Herman J. Fagin R. Gonsky Clonal origin of pituitary adenomas J Clin Endocrinol Metab 71 1990 1427 1433
57. S. Hinuma Y. Habata R. Fujii A prolactin-releasing peptide in the brain Nature 393 1998 272 276
58. K.Y. Ho G.A. Smythe P.J. Compton Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia Aust NZ J Med 15 1985 213 219
59. K.S. Honbo A.J.V. Herle K.A. Kellett Serum prolactin levels in untreated primary hypothyroidism Am J Med 64 1978 782 787
60. S.H. Hou S. Grossman M.E. Molitch Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis Am J Kidney Dis 6 1985 245 249
61. J.L. Hubbard M.D. Bernd W. Scheithauer Prolactin-secreting adenomas: The preoperative response to bromocriptine treatment and surgical outcome J Neurosurg 67 1987 816 821
62. L.S. Jacobs P.J. Snyder J.F. Wilber Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man J Clin Endocrinol Metab 33 1971 996 998
63. V.M. Jasonni R. Raffalli de March A. Vaginal bromocriptine in hyperprolactinemic patients and puerperal women Acta Obstet Gynecol Scand 70 1991 493 495
64. W.J. Jeffcoate N. Pound N.D.C. Sturrock Long-term follow-up of patients with hyperprolactinaemia Clin Endocrinol 45 1996 299 303
65. P.J. Jenkins A. Jain S.L. Jones Oral prednisolone supplement abolishes the acute adverse effects following initiation of depot bromocriptine therapy Clin Endocrinol 45 1996 447 451
66. P.W. Johansen O.P.F. Clausen E. Haug Effects of bromocriptine on cell cycle distribution and cell morphology in cultured rat pituitary adenoma cells Acta Endocrinol 110 1985 319 328
67. D.G. Johnston K. Hall P. Kendall-Taylor Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas Lancet 2 1984 187 192
68. D.G. Johnston R.W.G. Prescott P. Kendall-Taylor Hyperprolactinemia: Long-term effects of bromocriptine Am J Med 75 1983 868 874
69. Y. Kato Y. Iwasaki J. Iwasaki Prolactin release by vasoactive intestinal polypeptide in rats Endocrinology 103 1978 554 558
70. E. Katz H.F. Schran E.Y. Adashi Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: A novel approach to intolerance of oral therapy Obstet Gynecol 73 1989 517 520
71. E. Katz H.F. Schran B.E. Weiss Increased circulating levels of bromocriptine after vaginal compared with oral administration Fertil Steril 55 1991 882 884
72. S.R. Kelley T.J. Kamal M.E. Molitch Mechanism of verapamil calcium channel blockade–induced hyperprolactinemia Am J Physiol 270 Endocrinol Metab 33 1996 E96 100
73. P. Kendall-Taylor K. Hall D.G. Johnston Reduction in size of prolactin-secreting tumors in men treated with pergolide BMJ 285 1982 465 467
74. Kleinberg D.L. Boyd A.E. III S. Wardlaw Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone N Engl J Med 309 1983 704 709
75. O.A. Kletzky R. Borenstein G.N. Mileikowsky Pergolide and bromocriptine for the treatment of patients with hyperprolactinemia Am J Obstet Gynecol 154 1986 431 435
76. A. Klibanski Further evidence for a somatic mutation theory in the pathogenesis of human pituitary tumors J Clin Endocrinol Metab 71 1990 1415
77. J.G. Kok A.K.M. Bartelink B.P.M. Schulte Cerebrospinal fluid rhinorrhea during treatment with bromocriptine for prolactinoma Neurology 35 1985 1193 1195
78. P. Konopka J.P. Raymond R.E. Merceron Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas Am J Obstet Gynecol 146 1983 935 993
79. M.C.S. Koppelman M.J. Jaffe K.G. Rieth Hyperprolactinemia, amenorrhea, and galactorrhea Ann Intern Med 100 1984 115 121
80. K. Kovacs L. Stefaneanu E. Horvath Effect of dopamine agonist medication on prolactin producing pituitary adenomas: A morphological study including immunocytochemistry, electron microscopy and in situ hybridization Virchows Arch 418 1991 439 446
81. P. Krupp C. Monka Bromocriptine in pregnancy: Safety aspects Klin Wochenschr 65 1987 823 827
82. S.W.J. Lamberts R.F.P. Quik A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia J Clin Endocrinol Metab 72 1991 635 641
83. A.M. Landolt V. Osterwalder Perivascular fibrosis in prolactinomas: Is it increased by bromocriptine? J Clin Endocrinol Metab 58 1984 1179 1183
84. G. Langer E.J. Sachar Dopaminergic factors in human prolactin regulation: Effects of neuroleptics and dopamine Psychoneuroendocrinology 2 1977 373 378
85. P.A. Lee M.R. Kelly J.D. Wallin Increased prolactin levels during reserpine treatment of hypertensive patients JAMA 235 1976 2316 2317
86. L. Lemberger R. Crabtree J.T. Callaghan Pergolide, a potent long-acting dopamine-receptor agonist Clin Pharmacol Ther 27 1980 642 651
87. A. Liuzzi D. Dallabonzana M.D. Giuseppe Low doses of dopamine agonists in the long-term treatment of macroprolactinomas N Engl J Med 313 1985 656 659
88. R.M. MacLeod J.E. Lehmeyer Suppression of pituitary tumor growth and function by ergot alkaloids Cancer Res 33 1973 849 855
89. T. Maeda T. Ushiroyama K. Okuda Effective bromocriptine treatment of a pituitary macroadenoma during pregnancy Obstet Gynecol 61 1983 117 121
90. C.M. March O.A. Kletzky V. Davajan Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas Am J Obstet Gynecol 139 1981 835 844
91. T.L. Martin M. Kim W.B. Malarkey The natural history of idiopathic hyperprolactinemia J Clin Endocrinol Metab 60 1985 855 858
92. F. Massoud O. Serri J. Hardy Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up Surg Neurol 45 1996 341 346
93. R.A. Maurer Dopaminergic inhibition of prolactin synthesis and prolactin messenger RNA accumulation in cultured pituitary cells J Biol Chem 255 1980 8092 8097
94. N.G. McElvaney P.G. Wilcox A. Churg Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease Arch Intern Med 148 1988 2231 2236
95. G.B. Melis M. Gambacciani A.M. Paoletti Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women J Clin Endocrinol Metab 65 1987 541 545
96. G.B. Melis V. Mais M. Gambacciani Reduction in the size of prolactin-producing pituitary tumor after cabergoline administration Fertil Steril 52 1989 412 415
97. H.Y. Meltzer V.S. Fang B.J. Tricou Effect of antidepressants on neuroendocrine axis in humans Costa E. Racagni G. Typical and Atypical Antidepressants: Clinical Practice 1982 Raven Press New York 303 316
98. J.H. Mendelson N.K. Mello S.K. Teoh Cocaine effects on pulsatile secretion of anterior pituitary, gonadal, and adrenal hormones J Clin Endocrinol Metab 69 1989 1256 1260
99. M.E. Molitch Pregnancy and the hyperprolactinemic woman N Engl J Med 312 1985 1365 1370
100. M.E. Molitch Pathogenesis of pituitary tumors Endocrinol Metab Clin North Am 16 1987 503 527
101. M.E. Molitch Prolactin Melmed S. The Pituitary 1995 Blackwell Science Cambridge, MA 136 186
102. M.E. Molitch Prolactinomas Melmed S. The Pituitary 1995 Blackwell Science Cambridge, MA 443 477
103. M.E. Molitch Pituitary incidentalomas Endocrinol Metab Clin North Am 26 1997 725 740
104. M.E. Molitch R.L. Elton R.E. Blackwell Bromocriptine as primary therapy for prolactin-secreting macroadenomas: Results of a prospective multicenter study J Clin Endocrinol Metab 60 1985 698 705
105. M.E. Molitch S. Reichlin Hypothalamic hyperprolactinemia: Neuroendocrine regulation of prolactin secretion in patients with lesions of the hypothalamus and pituitary stalk MacLeod R.M. Thorner M.O. Scapagnini U. Prolactin. Basic and Clinical Correlates 1985 Liviana Press Padova 709 719
106. M.E. Molitch S. Schwartz B. Mukherji Is prolactin secreted ectopically? Am J Med 70 1981 803 807
107. M.E. Molitch M.O. Thorner C. Wilson Management of prolactinomas J Clin Endocrinol Metab 82 1997 996 1000
108. M. Montini G. Pagani D. Gianola Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine J Clin Endocrinol Metab 63 1986 266 268
109. I. Morange A. Barlier I. Pellegrini Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy Eur J Endocrinol 135 1996 413 420
110. M.Y. Morgan A.W. Jakobovits M.B. Gore Serum prolactin in liver disease and its relationship to gynecomastia Gut 19 1978 170 174
111. H. Mori S. Mori Y. Saitoh Effects of bromocriptine on prolactin-secreting pituitary adenomas Cancer 56 1985 230 238
112. T. Motta N. Colombo de Vincentiis S. Vaginal cabergoline in the treatment of hyperprolactinemic patients intolerant to oral dopaminergics Fertil Steril 65 1996 440 442
113. T. Motta G. Maggi A. D'Alberton Twice weekly cabergoline treatment of macroprolactinoma J Obstet Gynecol 9 1989 334 335
114. M. Muratori C. Romano G. Gambino Prolactin responsiveness to peptide histidine methionine-27 in normal subjects and hyperprolactinemic patients Horm Res 42 1994 257 261
115. O. Narita T. Kimura N. Suganuma Relationship between maternal prolactin levels during pregnancy and lactation in women with pituitary adenoma Acta Obstet Gynaecol Jpn 37 1985 758 762
116. J.D. Neill S. Frawley P.M. Plotsky Dopamine in hypophysial stalk blood of the rhesus monkey and its role in regulating prolactin secretion Endocrinology 108 1981 489 494
117. K. Nikolics A.J. Mason E. Szonyi A prolactin-inhibiting factor within the precursor for human gonadotropin-releasing hormone Nature 316 1985 511 517
118. M. Nissim B. Ambrosi V. Bernasconi Bromocriptine treatment of macroprolactinomas: Studies on the time course of tumor shrinkage and morphology J Endocrinol 5 1982 409 415
119. J. Niwa T. Minase M. Mori Immunohistochemical, electron microscopic, and morphometric studies of human prolactinomas after short-term bromocriptine treatment Surg Neurol 28 1987 339 344
120. S.R. Page S.S. Nussey Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient J Obstet Gynecol 10 1989 156 158
121. P.E. Palmer S. Bogojavlensky A.K. Bhan Prolactinoma in wall of ovarian dermoid cyst with hyperprolactinemia Obstet Gynecol 75 1990 540 543
122. I. Pellegrini R. Rasolonjanahary G. Gunz Resistance to bromocriptine in prolactinomas J Clin Endocrinol Metab 69 1989 500 509
123. I. Pellegrini-Bouiller A. Morange-Ramos A. Barlier Pit-1 gene expression in human pituitary adenomas Horm Res 47 1997 251 258
124. P.J. Pernicone B.W. Scheithauer T.J. Sebo Pituitary carcinoma Cancer 79 1997 804 812
125. R.M. Perovich J.A. Lieberman W.W. Fleischhacker The behavioral toxicity of bromocriptine in patients with psychiatric illness J Clin Psychopharmacol 9 1989 417 422
126. M.H. Perrone P.M. Hinkle Regulation of pituitary receptors for thyrotropin releasing hormone by thyroid hormones J Biol Chem 253 1978 5168 5173
127. Pharmacia and Upjohn, Inc., Kalamazoo, MI; Data on file. October, 1997
128. P.M. Plotsky J.D. Neill Interactions of dopamine and thyrotropin-releasing hormone in the regulation of prolactin release in lactating rats Endocrinology 111 1982 168 173
129. A.E. Pontiroli L. Falsetti Development of pituitary adenoma in women with hyperprolactinaemia: Clinical, endocrine, and radiological characteristics BMJ 288 1984 515 518
130. P.T. Pullan W.M. Carroll T.M.H. Chakera Management of extra-sellar pituitary tumours with bromocriptine: Comparison of prolactin secreting and non-functioning tumours using half-field visual evoked potentials and computerised tomography Aust NZ J Med 15 1985 203 208
131. S.K. Quadri K.H. Meites J. Lu Ergot-induced inhibition of pituitary tumor growth in rats Science 176 1971 417 418
132. C. Rasmussen T. Bergh L. Wide Prolactin secretion and menstrual function after long-term bromocriptine treatment Fertil Steril 48 1987 550 554
133. J.P. Raymond E. Goldstein P. Konopka Follow-up of children born of bromocriptine-treated mothers Horm Res 22 1985 239 246
134. H.K. Rjosk R. Fahlbusch von Werder K. Spontaneous development of hyperprolactinaemia Acta Endocrinol 100 1982 333 336
135. E. Robert L. Musatti G. Piscitelli Pregnancy outcome after treatment with the ergot derivative, cabergoline Reprod Toxicol 10 1996 333 337
136. V. Ruiz-Velasco G. Tolis Pregnancy in hyperprolactinemic women Fertil Steril 41 1984 793 805
137. S.I. Said J.C. Porter Vasoactive intestinal polypeptide: Release into hypophyseal portal blood Life Sci 24 1979 227 230
138. J. Schlechte K. Dolan B. Sherman The natural history of untreated hyperprolactinemia: A prospective analysis J Clin Endocrinol Metab 68 1989 412 418
139. H.R. Schran S.I. Bhuta H.J. Schwarz The pharmacokinetics of bromocriptine in man Goldstein M. Calne D. Lieberman A. Thorner M. Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects 1980 Raven Press New York 125 189
140. D. Schwarzstein A. Garcia-Patterson G. Giménez Dopaminergic resistance in a case of invasive macroprolactinoma J Endocrinol Invest 16 1993 443 447
141. T.P. Segerson J. Kauer H.C. Wolfe Thyroid hormone regulates TRH biosynthesis in the paraventricular nucleus of the rat hypothalamus Science 238 1987 78 80
142. D.R. Sibley I. Creese Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors Mol Pharmacol 23 1983 585 593
143. G.D. Sievertsen V.S. Lim C. Nakawatase Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure J Clin Endocrinol Metab 50 1980 846 851
144. D.A. Sisam J.P. Sheehan L.R. Sheeler The natural history of untreated microprolactinomas Fertil Steril 48 1987 67 71
145. S.L. Slater S. Lipper D.J. Shiling Elevation of plasma-prolactin by monoamine oxidase inhibitors Lancet 2 1977 275 276
146. A.V. Sluijmer R.E. Lappöhn Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia Fertil Steril 58 1992 72 77
147. C.E. Soto-Albors J.F. Randolph Y.K. Ying Medical management of hyperprolactinemia: A lower dose of bromocriptine may be effective Fertil Steril 48 1987 213 217
148. S.G. Soule J. Farhi G.S. Conway The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy Clin Endocrinol 44 1996 711 716
149. J. Steiner J. Cassar K. Mashiter Effect of methyldopa on prolactin and growth hormone BMJ 1 1976 1186 1188
150. 3H-N-n-propylinorapomorphine Eur J Pharmacol 187 1990 399 408
151. T.D. Stryker M.E. Molitch Reversible hyperthyrotropinemia, hyperthyroxinemia and hyperprolactinemia due to adrenal insufficiency Am J Med 79 1985 271 276
152. M.O. Thorner W.H. Martin A.D. Rogol Rapid regression of pituitary prolactinomas during bromocriptine treatment J Clin Endocrinol Metab 51 1980 438 445
153. M.O. Thorner R.L. Perryman A.D. Rogol Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine J Clin Endocrinol Metab 53 1981 480 483
154. M.O. Thorner H.F. Schran W.S. Evans A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine J Clin Endocrinol Metab 50 1980 1026 1033
155. G.T. Tindall K. Kovacs E. Horvath Human prolactin-producing adenomas and bromocriptine: A histological, immunocytochemical, ultrastructural, and morphometric study J Clin Endocrinol Metab 55 1982 1178 1183
156. R.W. Tsang J.D. Brierley T. Panzarella Role of radiation therapy in clinical hormonally active pituitary adenomas Radiother Oncol 41 1996 45 53
157. T.H. Turner J.C. Cookson J.A.H. Wass Psychotic reactions during treatment of pituitary tumours with dopamine agonists BMJ 289 1984 1101 1103
158. M.L. Vance J.R. Cragun C. Reimnitz CV 205-502 treatment of hyperprolactinemia J Clin Endocrinol Metab 68 1989 336 339
159. M.L. Vance M. Lipper A. Klibanski Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502 Ann Intern Med 112 1990 668 673
160. Van Roon E. van der Vijver J.C.M. G. Gerretsen Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy Fertil Steril 36 1981 173 177
161. Van't Verlaat J.W. R.J.M. Croughs Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: Effect on plasma prolactin and tumour size Clin Endocrinol 34 1991 175 178
162. M. Vermesh G.T. Fossum O.A. Kletzky Vaginal bromocriptine: Pharmacology and effect on serum prolactin in normal women Obstet Gynecol 72 1988 693 698
163. Von Werder K. T. Eversmann R. Fahlbusch Development of hyperprolactinemia in patients with adenomas with and without prior operative treatment Excerpta Med Int Congr Ser 584 1982 175 188
164. C. Wang K.S.L. Lam J.T.C. Ma Long-term treatment of hyperprolactinaemia with bromocriptine: Effect of drug withdrawal Clin Endocrinol 27 1987 363 371
165. A. Warfield D.M. Finkel N.J. Schatz Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function Ann Intern Med 101 1984 783 785
166. J. Webster G. Piscitelli Polli A. for the Cabergoline Comparative Study Group A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea N Engl J Med 331 1994 904 909
167. M.H. Weiss J. Teal P. Gott Natural history of microprolactinomas: Six-year follow-up Neurosurgery 12 1983 180 183
168. M.H. Weiss R.R. Wycoff R. Yadley Bromocriptine treatment of prolactin-secreting tumors: Surgical implications Neurosurgery 12 1983 640 642
169. F. Wollesen T. Andersen A. Karle Size reduction of extrasellar pituitary tumours during bromocriptine treatment Ann Intern Med 96 1982 281 286